Literature DB >> 21840358

The NYCBH vaccinia virus deleted for the innate immune evasion gene, E3L, protects rabbits against lethal challenge by rabbitpox virus.

Karen L Denzler1, Amanda D Rice, Amy L MacNeill, Nobuko Fukushima, Scott F Lindsey, Greg Wallace, Andrew M Burrage, Andrew J Smith, Brandi R Manning, Daniele M Swetnam, Stacey A Gray, R W Moyer, Bertram L Jacobs.   

Abstract

Vaccinia virus deleted for the innate immune evasion gene, E3L, has been shown to be highly attenuated and yet induces a protective immune response against challenge by homologous virus in a mouse model. In this manuscript the NYCBH vaccinia virus vaccine strain was compared to NYCBH vaccinia virus deleted for E3L (NYCBHΔE3L) in a rabbitpox virus (RPV) challenge model. Upon scarification, both vaccines produced a desired skin lesion, although the lesion produced by NYCBHΔE3L was smaller. Both vaccines fully protected rabbits against lethal challenge by escalating doses of RPV, from 10LD(50) to 1000LD(50). A single dose of NYCBHΔE3L protected rabbits from weight loss, fever, and clinical symptoms following the lowest dose challenge of 10LD(50), however it allowed a moderate level of RPV replication at the challenge site, some spread to external skin and mucosal surfaces, and increased numbers of secondary lesions as compared to vaccination with NYCBH. Alternately, two doses of NYCBHΔE3L fully protected rabbits from weight loss, fever, and clinical symptoms, following challenge with 100-1000LD(50) RPV, and it prevented development of secondary lesions similar to protection seen with NYCBH. Finally, vaccination with either one or two doses of NYCBHΔE3L resulted in similar neutralizing antibody titers following RPV challenge as compared to titers obtained by vaccination with NYCBH. These results support the efficacy of the attenuated NYCBHΔE3L in protection against an orthologous poxvirus challenge.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840358      PMCID: PMC3190037          DOI: 10.1016/j.vaccine.2011.07.140

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  A role for Z-DNA binding in vaccinia virus pathogenesis.

Authors:  Yang-Gyun Kim; Maneesha Muralinath; Teresa Brandt; Matthew Pearcy; Kevin Hauns; Ky Lowenhaupt; Bertram L Jacobs; Alexander Rich
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-30       Impact factor: 11.205

Review 2.  Interferons and their actions.

Authors:  S Pestka; J A Langer; K C Zoon; C E Samuel
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

3.  A prospective study of serum antibody and protection against smallpox.

Authors:  T M Mack; J Noble; D B Thomas
Journal:  Am J Trop Med Hyg       Date:  1972-03       Impact factor: 2.345

4.  Binding of complement subcomponent C1q to mouse IgG1, IgG2a and IgG2b: a novel C1q binding assay.

Authors:  R J Leatherbarrow; R A Dwek
Journal:  Mol Immunol       Date:  1984-04       Impact factor: 4.407

5.  Isolation and preliminary characterization of temperature-sensitive mutants of vaccinia virus.

Authors:  R C Condit; A Motyczka
Journal:  Virology       Date:  1981-08       Impact factor: 3.616

6.  Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus.

Authors:  R C Condit; A Motyczka; G Spizz
Journal:  Virology       Date:  1983-07-30       Impact factor: 3.616

7.  Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model.

Authors:  T A Brandt; B L Jacobs
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Roles of vaccinia virus genes E3L and K3L and host genes PKR and RNase L during intratracheal infection of C57BL/6 mice.

Authors:  Amanda D Rice; Peter C Turner; Jennifer E Embury; Lyle L Moldawer; Henry V Baker; Richard W Moyer
Journal:  J Virol       Date:  2010-10-13       Impact factor: 5.103

9.  Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia.

Authors:  L G Payne
Journal:  J Gen Virol       Date:  1980-09       Impact factor: 3.891

10.  Evidence that vaccinia virulence factor E3L binds to Z-DNA in vivo: Implications for development of a therapy for poxvirus infection.

Authors:  Yang-Gyun Kim; Ky Lowenhaupt; Doo-Byoung Oh; Kyeong Kyu Kim; Alexander Rich
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-02       Impact factor: 11.205

View more
  6 in total

Review 1.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

Review 2.  Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory.

Authors:  Jonas D Albarnaz; Alice A Torres; Geoffrey L Smith
Journal:  Viruses       Date:  2018-02-28       Impact factor: 5.048

3.  Crocodilepox Virus Protein 157 Is an Independently Evolved Inhibitor of Protein Kinase R.

Authors:  M Julhasur Rahman; Loubna Tazi; Sherry L Haller; Stefan Rothenburg
Journal:  Viruses       Date:  2022-07-19       Impact factor: 5.818

4.  Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques.

Authors:  Karen L Denzler; Tahar Babas; Amy Rippeon; Trung Huynh; Nobuko Fukushima; Lowrey Rhodes; Peter M Silvera; Bertram L Jacobs
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 4.169

5.  Rabbitpox in New Zealand White Rabbits: A Therapeutic Model for Evaluation of Poxvirus Medical Countermeasures Under the FDA Animal Rule.

Authors:  Mark R Perry; Richard Warren; Michael Merchlinsky; Christopher Houchens; James V Rogers
Journal:  Front Cell Infect Microbiol       Date:  2018-10-05       Impact factor: 5.293

6.  Identification of protective T-cell antigens for smallpox vaccines.

Authors:  Jun Ando; Minhtran C Ngo; Miki Ando; Ann Leen; Cliona M Rooney
Journal:  Cytotherapy       Date:  2020-05-08       Impact factor: 6.196

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.